Towards harmonizing clinical linear energy transfer (LET) reporting in proton radiotherapy: a European multi-centric study.


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Feb 2022
Historique:
pubmed: 24 10 2021
medline: 5 2 2022
entrez: 23 10 2021
Statut: ppublish

Résumé

Clinical data suggest that the relative biological effectiveness (RBE) in proton therapy (PT) varies with linear energy transfer (LET). However, LET calculations are neither standardized nor available in clinical routine. Here, the status of LET calculations among European PT institutions and their comparability are assessed. Eight European PT institutions used suitable treatment planning systems with their center-specific beam model to create treatment plans in a water phantom covering different field arrangements and fulfilling commonly agreed dose objectives. They employed their locally established LET simulation environments and procedures to determine the corresponding LET distributions. Dose distributions Treatment plans from six institutions fulfilled all clinical goals and were eligible for common analysis. Harmonizing the reported LET among PT centers is feasible and allows for consistent multi-centric analysis and reporting of tumor control and toxicity in view of a variable RBE. It may serve as basis for harmonized variable RBE dose prescription in PT.

Sections du résumé

BACKGROUND BACKGROUND
Clinical data suggest that the relative biological effectiveness (RBE) in proton therapy (PT) varies with linear energy transfer (LET). However, LET calculations are neither standardized nor available in clinical routine. Here, the status of LET calculations among European PT institutions and their comparability are assessed.
MATERIALS AND METHODS METHODS
Eight European PT institutions used suitable treatment planning systems with their center-specific beam model to create treatment plans in a water phantom covering different field arrangements and fulfilling commonly agreed dose objectives. They employed their locally established LET simulation environments and procedures to determine the corresponding LET distributions. Dose distributions
RESULTS RESULTS
Treatment plans from six institutions fulfilled all clinical goals and were eligible for common analysis.
CONCLUSION CONCLUSIONS
Harmonizing the reported LET among PT centers is feasible and allows for consistent multi-centric analysis and reporting of tumor control and toxicity in view of a variable RBE. It may serve as basis for harmonized variable RBE dose prescription in PT.

Identifiants

pubmed: 34686122
doi: 10.1080/0284186X.2021.1992007
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-214

Auteurs

Christian Hahn (C)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Physics and Radiotherapy, Department of Physics, TU Dortmund University, Dortmund, Germany.

Jakob Ödén (J)

RaySearch Laboratories AB, Stockholm, Sweden.

Alexandru Dasu (A)

The Skandion Clinic, Uppsala, Sweden.
Medical Radiation Sciences, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Anne Vestergaard (A)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Maria Fuglsang Jensen (M)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Olga Sokol (O)

GSI Helmholtz Centre for Heavy Ion Research, Darmstadt, Germany.

Claudia Pardi (C)

I-SEE (Internet-Simulation Evaluation Envision), Torino, Italy.

Faiza Bourhaleb (F)

I-SEE (Internet-Simulation Evaluation Envision), Torino, Italy.

Amélia Leite (A)

Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, Orsay, France.

Ludovic de Marzi (L)

Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, Orsay, France.
Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, Orsay, France.

Edward Smith (E)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Adam Aitkenhead (A)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Christopher Rose (C)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Michael Merchant (M)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Karen Kirkby (K)

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Leszek Grzanka (L)

Institute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland.

Jörg Pawelke (J)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany.

Armin Lühr (A)

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Physics and Radiotherapy, Department of Physics, TU Dortmund University, Dortmund, Germany.
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH